BTCC hits $3.7 trillion in trading volume in 2025, RWA expansions and the growing user base to 11 million, with plans for AI-powered trading in 2026.BTCC hits $3.7 trillion in trading volume in 2025, RWA expansions and the growing user base to 11 million, with plans for AI-powered trading in 2026.

BTCC Breaks Records with $3.7 Trillion Trading Volume in 2025, Sets Sights on 2026 Growth

btcc959

BTCC, a leading crypto exchange with 11M+ global user base, has reported a record year for 2025, marking significant milestones in trading volume and user expansion. The cryptocurrency exchange had a total trading volume of $3.7 trillion, an increment of 60% over the past few years. BTTC also past 11 million active users, which reflects the increasing international presence as it approaches its 15th anniversary in 2026.

BTCC’s Major Expansion in Trading Segments

The trading segments of BTCC experienced a significant growth in 2025. The exchange recorded 3.27 trillion in the volume of futures trading and 431 billion in the spot trading. One of the most important growth points was the Tokenized Real-World Asset (RWA) trading, whose volume increased between Q1 (1.2 billion) and Q4 (22.7 billion).

Overall, the volume of futures trading that was tokenized (in terms of volume) was of $53.1 billion in the year. This increased the amount of tokenized RWA trading, and this showed that BTCC was in a good position in the market. The quarterly volumes grew steadily, and they indicate that the exchange was successful in attracting market demand in these new types of assets.

BTCC has continued to focus on transparency and has kept up with its monthly Proof of Reserves (PoR) reports throughout the year. This accountability had made sure that the reserves would always remain at a level above 100% level. These steps made BTCC stronger in terms of its reputation for safe and trusted services.

Growth and Mergers to Increase Brand Awareness

BTCC in 2025 is an expansion of its international reach by attending several high-profile events. These were TOKEN2049 in Dubai and Singapore, a Summer Festival in Tokyo, and Red Eagle Foundation-sponsored charity golf events. These activities contributed to raising more than $100,000 as a charity activity to depict that BTCC cares about the community.

Another strategic move made by the exchange was the creation of brand visibility through partnering. It is worth noting that NBA All-Star Jaren Jackson Jr. was chosen as the first global brand ambassador by BTCC. This collaboration will help to fill the void between sports and cryptocurrency and bring more people to the services of BTCC.

The industry had noticed BTCC in its bid to expand the brand. The exchange was the winner of the BelnCrypto Best Centralized Exchange (Community Choice) award. This was another recognition that enhanced the good reputation of BTCC and its honorable mission to offer quality services.

2026 Strategic Focus: Innovation and Expansion

Having a prospective view of 2026, BTCC has provided strategic priorities towards further growth. The business will also create AI-driven trading capabilities, which will help it improve the trading process. The new tools will combine AI with conventional trading means by providing a smoother and user-friendly platform.

BTCC is also a goal of growing its tokenized RWA market, with other types of assets and trading pairs. This diversification emphasis is an indication of increased demand for the same. A new, sophisticated trading platform will offer more choices to the users with risk-specific strategies based on varying risk profiles.

While commenting on the visionary grounds of the exchange, Marcus Chen, the Product Manager at BTCC stated, “15 years in this industry has taught us that the real risk isn’t change but standing still. Our focus for 2026 is translating operational experience into speed: building what traders need for where markets are heading, not where they’ve been.”

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26